Form 4 SAB Biotherapeutics, For: Jul 15 Filed by: SKYLER JAY S
![SEC EDGAR](../../../Content/images/providers/SC.png)
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: SEC EDGAR
![SEC EDGAR](../../../Content/images/providers/SC.png)
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into SAB Biotherapeupeutics, Inc.Accesswire
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into SAB BiotherapAccesswire
- SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual MeetingGlobeNewswire
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $12.00 price target on the stock.MarketBeat
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
SABS
Earnings
- 5/20/24 - Beat
SABS
Sec Filings
- 8/13/24 - Form 4
- 8/12/24 - Form S-8
- 8/8/24 - Form 10-Q
- SABS's page on the SEC website